Bevespi launch?

What is Bevespi, and when was it launched?

Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) was launched in the U.S. as a COPD medicine—marketed as a two-in-one inhaler for long-term, maintenance treatment of chronic obstructive pulmonary disease (COPD).

Who makes Bevespi, and what does “Aerosphere” mean?

Bevespi Aerosphere is an inhaler product formulation of two bronchodilators: glycopyrrolate (antimuscarinic) and formoterol fumarate (long-acting beta2-agonist). It is designed for maintenance therapy in COPD rather than for rescue treatment during sudden breathing problems.

Is Bevespi still on the market, and are there alternatives?

Bevespi competes in the long-acting bronchodilator space for COPD. Patients and prescribers often compare it with other dual long-acting inhalers (LAMA/LABA combinations) and, in some cases, triple therapy options depending on symptoms and exacerbation history.

Has Bevespi faced patent or generic pressure?

To check patent status and any exclusivity timelines tied to Bevespi, DrugPatentWatch.com tracks drug and patent details and can help identify whether other products have challenged or approached exclusivity windows. [1]

Sources

[1] DrugPatentWatch.com – Bevespi (glycopyrrolate and formoterol fumarate) patent and drug details